Evidence map›Paper›PMID 40253665›Full record

ArticleHuman cell2025

Establishment and characterization of NCC-PS2-C1: a novel cell line of high-grade pleomorphic spindle cell sarcoma, most consistent with myxofibrosarcoma.

Shuhei Iwata, Rei Noguchi, Julia Osaki, Yuki Adachi, Yomogi Shiota, Shuhei Osaki, Shogo Nishino, Akihiko Yoshida, Seiji Ohtori, Akira Kawai and 1 more

Abstract read
PubMed Publisher
In one paragraph

Article in Human cell, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Shuhei IwataDivision of Rare Cancer Research, National Cancer Center Research Institute, 5 - 1- 1 Tsukiji, Chuo-ku, Tokyo, 104 - 0045, Japan.
Rei NoguchiDivision of Rare Cancer Research, National Cancer Center Research Institute, 5 - 1- 1 Tsukiji, Chuo-ku, Tokyo, 104 - 0045, Japan.
Julia OsakiDivision of Rare Cancer Research, National Cancer Center Research Institute, 5 - 1- 1 Tsukiji, Chuo-ku, Tokyo, 104 - 0045, Japan.
Yuki AdachiDivision of Rare Cancer Research, National Cancer Center Research Institute, 5 - 1- 1 Tsukiji, Chuo-ku, Tokyo, 104 - 0045, Japan.
Yomogi ShiotaDivision of Rare Cancer Research, National Cancer Center Research Institute, 5 - 1- 1 Tsukiji, Chuo-ku, Tokyo, 104 - 0045, Japan.
Shuhei OsakiDivision of Musculoskeletal Oncology and Rehabilitation, National Cancer Center Hospital, 5 - 1- 1 Tsukiji, Chuo-ku, Tokyo, 104 - 0045, Japan.
Shogo NishinoDepartment of Diagnostic Pathology, National Cancer Center Hospital, 5 - 1- 1 Tsukiji, Chuo-ku, Tokyo, 104 - 0045, Japan.
Akihiko YoshidaDepartment of Diagnostic Pathology, National Cancer Center Hospital, 5 - 1- 1 Tsukiji, Chuo-ku, Tokyo, 104 - 0045, Japan.
Seiji OhtoriDepartment of Orthopaedic Surgery, Graduate School of Medicine, Chiba University, 1 - 8- 1 Inohana, Chuo-ku, Chiba-Shi, 260 - 0856, Japan.
Akira KawaiDivision of Musculoskeletal Oncology and Rehabilitation, National Cancer Center Hospital, 5 - 1- 1 Tsukiji, Chuo-ku, Tokyo, 104 - 0045, Japan.
Tadashi KondoDivision of Rare Cancer Research, National Cancer Center Research Institute, 5 - 1- 1 Tsukiji, Chuo-ku, Tokyo, 104 - 0045, Japan. takondo@ncc.go.jp.ORCID http://orcid.org/0000-0001-6405-7792

Funding

japan agency for medical research and development 20ck0106537h
6 · The paper itself

Abstract

Pleomorphic sarcoma (PS) is a heterogeneous group of malignant mesenchymal tumors that lack specific histological differentiation. PS is characterized by genetic instability and diversity and unique histological features such as pronounced morphologic pleomorphism. PS is one of the most common soft tissue sarcomas. Complete surgical resection remains the only curative treatment and is often combined with neoadjuvant radiotherapy. Effective systemic chemotherapy is yet to be established, and PS frequently recurs locally and metastasizes to the lungs. Patient-derived cancer cell lines are invaluable tools for basic and preclinical research for developing novel chemotherapies. Herein, we report a high-grade pleomorphic spindle cell sarcoma, most consistent with myxofibrosarcoma cell line, NCC-PS2-C1, which was derived from a primary tumor specimen. NCC-PS2-C1 cells exhibited a range of copy number alterations. This cell line demonstrated consistent proliferation, spheroid formation, and invasive capabilities in vitro. Drug screening using NCC-PS2-C1 cells revealed that cobimetinib, crenolanib, and ixazomib were effective against PS. In conclusion, we established NCC-PS2-C1 cells from primary tumors of PS. This cell line is a valuable resource for developing novel chemotherapies.

Indexed as

FibrosarcomaSarcomaSoft Tissue NeoplasmsAntineoplastic AgentsCell Line, TumorCell ProliferationDrug Screening Assays, AntitumorHumansNeoplasm GradingNeoplasm InvasivenessAntineoplastic AgentsAntitumor drug screeningNeoadjuvant radiotherapyPatient-derived cell linePleomorphic sarcomaSoft tissue sarcoma

Identifiers

PMID40253665

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.